Skip to content
false
Fred, Snikeris Avatar

Fred Snikeris

Fred Snikeris, PhD is an established biometrics executive with extensive Pharmaceutical R&D and CRO experience. He has built self-sustaining global multi-site biostatistics departments in support of late phase and early phase clinical development and preclinical research efforts.
  • Read: Phase I Clinical Trial Designs: Modified Toxicity Probability Interval Modified Toxicity Probability Interval

    Clinical Trials - Early Phase Research - Oncology

    Phase I Clinical Trial Designs: Modified Toxicity Probability Interval

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778869, hs_child_table_id=0, hs_updated_at=1715692377826, hs_published_at=1738849393727, description=Fred Snikeris, PhD is an established biometrics executive with extensive Pharmaceutical R&D and CRO experience. He has built self-sustaining global multi-site biostatistics departments in support of late phase and early phase clinical development and preclinical research efforts., avatar=Image{width=720,height=812,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Fred-Snikeris.png',altText='Fred-Snikeris',fileId=167370698299}, linkedin=https://www.linkedin.com/in/fredsnikeris, hs_name=, hs_path=, lastname=Snikeris, hs_initial_published_at=1716212769184, hs_created_at=1709645745100, hs_is_edited=false, hs_deleted_at=0, name=Fred, job=, slug=fred-snikeris, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
    • Fred Snikeris avatar

      Fred Snikeris

    Discover
Loading...
You've reach the end